Table 4 Prevalence of ERBB2 expression and amplification in KRAS exon 2 WT patients in the archival and screening cohorts
From: Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
Cohort | Patients | Immunohistochemistry 0 | Immunohistochemistry 1+ | Immunohistochemistry 2+ | Immunohistochemistry 3+ | Total overexpressed 2+/3+ a | Total amplified b | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N | % | Amplified c | N | % | Amplified c | N | % | Amplified c | % over 2+ | N | % | Amplified c | % over 3+ | N | % | N | % | ||
Archivald | 256 | 131 | 51.2% | 0 | 90 | 35.2% | 0 | 23 | 9.0% | 1 | 4.3% | 12 | 4.7% | 12 | 100.0% | 35 | 13.7% | 13 | 5.1% |
Screeningd | 830 | 610 | 73.5% | —e | 150 | 18.1% | —e | 37 | 4.5% | 10 | 27.0% | 33 | 4.0% | 33 | 100.0% | 70 | 8.4% | 43 | 5.2% |
Total | 1086 | 741 | 68.2% | NA | 240 | 22.1% | NA | 60 | 5.5% | 11 | 18.3% | 45 | 4.1% | 45 | 100.0% | 105 | 9.7% | 56 | 5.2% |
